Patrick J. Mcenany - Nov 18, 2022 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
President and CEO, Director
Signature
/s/ Patrick J. McEnany
Stock symbol
CPRX
Transactions as of
Nov 18, 2022
Transactions value $
-$6,647,500
Form type
4
Date filed
11/22/2022, 04:00 PM
Previous filing
Sep 15, 2022
Next filing
Dec 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $784K +350K +8.97% $2.24* 4.25M Nov 18, 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$5.47M -350K -8.23% $15.62 3.9M Nov 18, 2022 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $336K +150K +3.84% $2.24* 4.05M Nov 21, 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$2.3M -150K -3.7% $15.33 3.9M Nov 21, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -350K -10.4% $0.00 3.02M Nov 18, 2022 Common Stock 350K $2.24 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -150K -4.97% $0.00 2.87M Nov 21, 2022 Common Stock 150K $2.24 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold for personal reasons. Shares were not sold as a result of any disagreement with the Company and Mr. McEnany remains a director and an officer of the Company.
F2 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $15.50 to $16.06 per share.
F3 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $15.19 to $15.55 per share.
F4 Options vested in three equal tranches on December 19, 2019, 2020 and 2021.